ALLERGY IMMUNOTHERAPY MARKET ANALYSIS

Regional Analysis

To learn more about this report, Request sample copy

North America remains the dominant region in the global allergy immunotherapy market and is estimated to hold 38.1% of the market share in 2024. The presence of leading pharmaceutical and biotechnology companies in the U.S. and Canada has propelled research and development activities in the region. Favorable reimbursement policies for immunotherapy procedures have ensured wider acceptance and adoption among patients and healthcare providers. Manufacturers in North America have developed a wide range of immunotherapy products for different allergens. The region is also home to several manufacturing facilities that cater to local as well as global demand. This enables companies to strengthen supply chain managements and address customer needs in a time-efficient manner.

Asia Pacific region has emerged as the fastest growing market for allergy immunotherapy. Rapid economic growth, rising healthcare standards, and growing incidences of allergies across nations like India and China are expected to drive the market growth. Local players are collaborating with global leaders to transfer technology and expertise. Governments are also introducing favorable regulations to boost indigenous manufacturing capabilities in the long term.